RG6139 (RO7247669)
Hepatocellular Carcinoma
Key Facts
About Chugai Pharmaceutical
Chugai Pharmaceutical's mission is to create innovative, best-in-class therapeutics that contribute to human health worldwide, with a strategic focus on oncology and niche specialty areas. Its defining achievement is the construction of a highly successful, decades-long strategic alliance with Roche, which provides a unique two-way pipeline flow, global scale, and financial stability. The company's strategy centers on maintaining a powerful independent R&D engine to generate proprietary assets while simultaneously co-developing and commercializing Roche's global portfolio in its key markets. This model has established Chugai as Japan's premier biopharmaceutical innovator and a vital node in Roche's global network.
View full company profileTherapeutic Areas
Other Hepatocellular Carcinoma Drugs
| Drug | Company | Phase |
|---|---|---|
| Namodenoson (CF102) | Can Fite Biopharma | Phase IIb/III |
| GC-101 | Genocury Biotech | Preclinical |
| DCR-MYC | Dicerna Pharmaceuticals | Preclinical |
| RYZ801 | RayzeBio | Preclinical |
| CT011 | CARsgen Therapeutics | Phase II |
| BRVT101 | Biorevert | Preclinical |
| BRVT121 | Biorevert | Phase I |
| BRVT151 | Biorevert | Phase I |
| HCC Diagnostic Test | Senseera | Clinical POC |
| ALN-BCAT | Alnylam Pharmaceuticals | Phase 1 |
| HCC Program | Arcellx | Discovery |
| TTFields | Novocure | Pilot |